Scientific progress can’t help people if they can’t access care

This is a policy problem. And it is one we can change.

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Scientific advances have produced therapies that allow some people with metastatic breast cancer to live longer and better. We want that progress to continue, and we will continue to fight for the right research necessary to achieve it. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Frances M. Visco, JD
President, National Breast Cancer Coalition
Michelle Tregear
Chief programs officer, National Breast Cancer Coalition
Table of Contents

YOU MAY BE INTERESTED IN

Artificial intelligence may help radiologists identify subtle signs of breast cancers that are missed during routine mammograms—and some AI systems may even identify patterns associated with an increased risk of cancer before it becomes visible on a mammogram—but there are still many significant limitations, according to a review led by investigators at the UCLA Health Jonsson Comprehensive Cancer Center.
FDA approved imlunestrant (Inluriyo) in combination with abemaciclib (Verzenio), for adults with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, estrogen receptor 1 (ESR1)-mutated advanced or metastatic breast cancer, as detected by an FDA-authorized test, with disease progression following at least one line of endocrine therapy. 
Frances M. Visco, JD
President, National Breast Cancer Coalition
Michelle Tregear
Chief programs officer, National Breast Cancer Coalition

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login